Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS Wild Type
Conditions
KRAS Wild Type, Resectable Type II Gastric Adenocarcinoma
Trial Timeline
— → —
NCT ID
NCT01351038About Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
Epirubicine, Oxaliplatin, Capecitabine, Panitumumab is a phase 2 stage product being developed by Amgen for KRAS Wild Type. The current trial status is terminated. This product is registered under clinical trial identifier NCT01351038. Target conditions include KRAS Wild Type, Resectable Type II Gastric Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01351038 | Phase 2 | Terminated |
Competing Products
20 competing products in KRAS Wild Type